TM3 Therapeutics

Biotechnology ResearchCalifornia, United States11-50 Employees

TM3 Therapeutics is a biotechnology research company based in Hayward, California, focused on developing metabolite replacement therapies for rare neurodegenerative and metabolic disorders. The firm’s work centers on preclinical and therapeutic programs aimed at addressing unmet needs in genetic neurological diseases, with its lead program TM-1803 (also referred to as P-PantSAc) highlighted in recent preclinical publications. The company serves clients and collaborators within the biotechnology and biopharmaceutical sectors seeking innovative approaches to treat rare conditions, particularly those involving metabolic and neurological pathways. Established in the biotechnology research landscape, TM3 Therapeutics positions itself through development efforts targeting Pantothenate Kinase-Associated Neurodegeneration and similar disorders, with leadership appointments signaling governance oversight. The organization presently operates from its Hayward location and maintains an active focus on advancing its therapeutic programs within the broader biotech industry. A notable development in its recent history includes the announcement of the TM-1803 lead compound and associated preclinical data, reflecting ongoing progress in its research agenda.

Sign up for free to view info

Email Format Employee directory